shares of Seelos Therapeutics Inc (SEEL) on
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York, New York and currently employs 5 full-time employees. The firm is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The firm is engaged in developing its lead programs SLS-002 and SLS-006. The firm is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson’s disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).